Latest news with #CART
Yahoo
19 hours ago
- Automotive
- Yahoo
Detroit Grand Prix: A quick history from F1 to Belle Isle to downtown
Downtown racing may feel like a new phenomenon for many Detroiters, but the history of the Detroit Grand Prix actually stretches back decades. If you want to get really historical, open-wheel racing in metro Detroit actually stretches back a century, back when Grosse Pointe hosted a non-championship event on Aug. 8, 1905. The winner of that race, by the way, was Jay Webb, who was born (1870) when there were only 37 states in the United States. Advertisement But that's ancient history — let's fast-forward a bit. GET READY TO RACE: 5 narratives to watch during 2025 Grand Prix downtown The modern edition of the Detroit Grand Prix started in 1982 and has had a bit of a bumpy existence (almost as bumpy as the downtown track itself). With a handful of starts and stops, open-wheel racing in Detroit could have ended as the result of many different events in the city's history. But 43 years after the first downtown race, the Grand Prix is back as a fixture on the IndyCar calendar. Here's a quick history of the many faces of the Detroit Grand Prix: 1982-88: The Formula 1 era Believe it or not, the Detroit Grand Prix started out as an Formula 1 race, not an IndyCar race, in downtown Detroit. Advertisement It was also arguably the least popular race on the F1 schedule at the time. The 1982 Detroit Grand Prix, on a course that included Beaubien, Congress and Larned streets in addition to Jefferson and Atwater along the river, was marred by scheduling issues, rain during the qualifiers and crashes during the main event, partially caused by a bumpy track (a recurring theme for the downtown course). The bumpy track, June heat and safety issues caused F1's governing body (FISA) to bow out of Detroit after the 1988 race, leaving the U.S. without an F1 race for the first time in 30 years. It wouldn't take long for open-wheel racing to return to the city, however. 1989-2001: CART and move to Belle Isle Walker Racing Team's driver Gil De Ferran, signs Wayne Ramocan's, 13, of Detroit, shirt of the Detroit Area Pre-college Engineering Programs summer PVP program, at the Grand Prix on Belle Isle, on August 5, 1999. The Paper Vehicle Program, is geared at introducing kids to the field of engineering. Championship Auto Racing Teams (CART), a predecessor (and eventual competitor) to IndyCar founded in 1979, brought a race back to downtown Detroit in 1989 and moved it to Belle Isle in 1992. Belle Isle hosted the race under CART until 2001, two years before the circuit folded. Advertisement The Belle Isle race provided some advantages to drivers (like a less bumpy ride) and some disadvantages for organizers and fans, who now had to make their way to an island to watch the event instead of landing downtown. The Belle Isle track lay dormant to open-wheel's biggest circuit as the sport reorganized itself in the early 2000s, but the Grand Prix returned to the island a few years later. 2007-19: Return to Belle Isle and doubleheader era IMSA Sports Car Classic competitors drive by James Scott fountain during the Detroit Grand Prix on Saturday June 1, 2019, on Belle Isle. IndyCar, the biggest current American open-wheel circuit, came back to Belle Isle in 2007 to a big crowd but shut down from 2009-2011 due to the recession and its economic impacts on Detroit. Advertisement When the race returned to Belle Isle in 2012, IndyCar turned the Detroit Grand Prix into a doubleheader, for a while the only doubleheader on the circuit's schedule. That meant drivers had back-to-back races during race weekend, often driving in three races during a seven-day span with the Indianapolis 500 usually scheduled for the weekend before the Detroit Grand Prix. The Grand Prix on Belle Isle had another pause in 2020 due to the coronavirus pandemic but returned to its doubleheader schedule in 2021. IndyCar returned in 2022 but dialed it back, turning the Grand Prix into a single race for its final event on Belle Isle. 2023-present: Return downtown Alex Palou (10) drives on the Detroit Grand Prix race track during the NTT IndyCar Series qualifying in downtown Detroit on Saturday, June 3, 2023. Palou won his second consecutive NTT P1 Award. After 32 years of pauses and Belle Isle races, the Grand Prix returned downtown with mixed results in 2023. Heat and a modest turnout for the refreshed event gave it a slightly muted feel for some, but organizers have been building up the event over the past two years to turn it into a staple of the IndyCar season. Advertisement Though the downtown course retains its trademark bumpiness (making it once again one of the most challenging races for many IndyCar drivers), the race weekend has turned into one of Detroit's can't-miss annual sporting events and (for many) the unofficial start to summer in the city. You can reach Christian at cromo@ This article originally appeared on Detroit Free Press: Detroit Grand Prix: Quick history from F1 to Belle Isle to Downtown
Mint
2 days ago
- Business
- Mint
Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial
Mumbai: Ichnos Glenmark Innovation (IGI), a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, on Monday shared promising results from an ongoing phase-1 trial of ISB 2001, a novel drug targeting relapsed or refractory multiple myeloma. The data, presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), showed an overall response rate (ORR) of 74% in heavily pre-treated patients. Refractory multiple myeloma refers to cases where the cancer does not respond or stops responding to treatment. Multiple myeloma is a rare, incurable blood cancer affecting plasma cells. While several therapies have been approved in recent years, most patients eventually relapse or become resistant, leaving limited treatment options. ISB 2001 is being developed by IGI to address this unmet need, particularly in patients who have previously received T-cell–based therapies such as CAR T-cells or bispecific antibodies. It is a first-in-class tri-specific antibody designed to simultaneously target BCMA, CD38, and CD3—three proteins associated with multiple myeloma. The drug aims to overcome resistance mechanisms seen with earlier-generation immunotherapies, while minimizing off-tumour toxicity. The phase-1 trial, known as TRIgnite-1, is evaluating the drug's safety and efficacy in patients who have exhausted standard treatment options. The latest data, from the full dose-escalation phase, covered 35 patients with a median of six prior lines of therapy. The overall response rate was 74%. 'The high response rates and low safety concerns demonstrated in the dose-escalation portion of the TRIgnite-1 study, conducted in a heavily pre-treated population across multiple types of therapies, reinforce the promise of ISB 2001 as a potential new treatment for patients,' said Lida Pacaud, M.D., chief medical officer at IGI. 'As we advance to the second part of the TRIgnite-1 study, our focus is now on defining the recommended dosing schedule and evaluating ISB 2001 in a larger population of heavily pre-treated RRMM patients, where we hope to observe similarly impressive treatment responses and tolerability,' Pacaud said. Among patients receiving higher, active dose levels (≥50 µg/kg), the ORR rose to 79%, with 30% achieving complete or stringent complete responses. Patients who had not previously received T-cell–based treatments saw an ORR of 84%. Even among those with prior exposure to CAR T or CD38-targeted therapies, response rates remained strong, ranging from 71% to 73%. The safety profile of ISB 2001 was favourable, with no dose-limiting toxicities reported. The most common side effect was cytokine release syndrome (CRS), seen in 69% of patients—mostly mild (Grade 1), with only four cases classified as moderate (Grade 2). There were no severe neurological adverse events. The market for multiple myeloma is projected to grow to about $33 billion by 2030, according to estimates by Bloomberg Intelligence. The trial has now entered its dose-expansion phase, which will determine the recommended Phase 2 dose and optimal dosing schedule. ISB 2001 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in 2023 and recently received Fast Track status, underscoring the agency's recognition of its potential.
Yahoo
4 days ago
- Business
- Yahoo
Maplebear Inc. (CART): A Bull Case Theory
We came across a bullish thesis on Maplebear Inc. (CART) on Chit Chat Stocks' Substack. In this article, we will summarize the bulls' thesis on CART. Maplebear Inc. (CART)'s share was trading at $47.02 as of 28th May. CART's trailing and forward P/E were 30.95 and 19.12 respectively according to Yahoo Finance. A delivery truck filled with grocery items heading to a local school. Instacart (CART) has emerged as the dominant third-party grocery delivery platform in the U.S., controlling over 70% market share among independent providers. Founded by Apoorva Mehta in 2012, the company scaled quickly by leveraging a 'ninja shopping' model—using independent shoppers to buy items in-store without grocer partnerships—and building a unique centralized SKU database. Instacart now reaches 98% of U.S. households, with approximately 8 million customers and 600,000 shoppers. The company monetizes through service and delivery fees, tips, and increasingly, advertising. Since 2021, advertising has grown rapidly and now contributes nearly $1 billion of Instacart's $3.5 billion in revenue, complementing the 6.5–7.5% take rate it earns on $34 billion in annual gross transaction volume. Ads appear across browsing, search, and post-order experiences, targeting CPG brands. Instacart boasts 75% gross margins and 24% free cash flow margins, supported by asset-light operations. Competitive concerns over Uber and DoorDash appear overstated due to Instacart's superior shopper quality and customer loyalty, particularly for large, complex grocery orders. While grocers like Walmart may pursue in-house delivery, most rely on Instacart for not only delivery but also e-commerce tools, inventory management, and white-label storefronts. CEO Fidji Simo, a former Facebook executive instrumental in its ads business, has driven growth but is departing for OpenAI. Instacart has bought back $2.2 billion in stock over two years, reducing its share count by 6%. While it lacks an impenetrable moat, Instacart occupies a sticky and underestimated strategic position in the evolving grocery and retail media ecosystem. For a comprehensive analysis of another standout stock covered by the same author, we recommend reading our summary of his bullish thesis on Airbnb, Inc. (ABNB). Since our coverage, the stock is up 1.6% as of 28th May. Maplebear Inc. (CART) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 64 hedge fund portfolios held CART at the end of the first quarter which was 60 in the previous quarter. While we acknowledge the risk and potential of CART as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CART but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
6 days ago
- Business
- Yahoo
Here's Why Maplebear (CART) is a Great Momentum Stock to Buy
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Maplebear (CART), a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Maplebear currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> In order to see if CART is a promising momentum pick, let's examine some Momentum Style elements to see if this operator of the Instacart grocery delivery service holds up. Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area. For CART, shares are up 2.91% over the past week while the Zacks Internet - Commerce industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 17.87% compares favorably with the industry's 8.4% performance as well. While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Maplebear have increased 21.84% over the past quarter, and have gained 52.07% in the last year. On the other hand, the S&P 500 has only moved -0.81% and 12.32%, respectively. Investors should also pay attention to CART's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. CART is currently averaging 4,581,467 shares for the last 20 days. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with CART. Over the past two months, 10 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost CART's consensus estimate, increasing from $1.61 to $1.70 in the past 60 days. Looking at the next fiscal year, 8 estimates have moved upwards while there have been 3 downward revisions in the same time period. Taking into account all of these elements, it should come as no surprise that CART is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Maplebear on your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Maplebear Inc. (CART) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Health
- Yahoo
Letters to the Editor: Two impassioned pleas from Californians who've benefited from experimental treatments
To the editor: Guest contributors Euan Ashley and Rachel Keranen made a compelling case for NIH grant funding as a valuable, proven investment ('Slashing NIH research guarantees a less healthy, less wealthy America,' May 28). I'm living proof that this is true. At 74, I live each day under the shadow of Alzheimer's. My mother began losing her memories in her late 60s, and I am genetically predisposed to the same fate. Yet today I remain mentally sharp, perhaps thanks to an experimental weekly dose of 6 mg of rapamycin. This drug isn't approved for Alzheimer's, but in my case, it seems to be working. I've seen firsthand how promising therapies can offer precious extra time of clarity. Still, I worry every day that the benefits will stop, that side effects will emerge or that others won't qualify for these trials at all. That fear is crushing and it's shared by millions of Americans who carry the same genetic risks. We've waited far too long for progress. It took decades for today's experimental drugs to reach human testing, and many never make it to approval. Barriers to clinical trials and off-label access leave families scrambling for hope. I urge our lawmakers to act now: Increase federal investment in Alzheimer's research, streamline compassionate-use pathways for experimental treatments and ensure Medicare and Medicaid cover innovative therapies. We cannot afford to slow down. Every day of delay costs precious memories and precious lives. Brian Valerie, Dana Point .. To the editor: The cutbacks in research funding have hit me hard as I worry about cancer patients in the United States who will ultimately pay the price. I have already heard from patients whose clinical trials have been shut down, impacting one 4-year-old childhood leukemia patient who will now likely lose his life. I was a cancer patient fighting an incurable form of non-Hodgkin lymphoma from 2006 until 2018. Diagnosed at the age of 46, I was in continuous treatment until age 58. My son was in kindergarten when I was diagnosed and spent his entire K-12 years with a sick mom. In 2012, when I was on my fifth treatment line, I heard about a phase 1 clinical trial at the National Institutes of Health/National Cancer Institute of a breakthrough individualized therapy called CAR T (chimeric antigen receptor T-cell therapy) for my type of cancer. The trial included only 17 patients, but the results were astonishing. Seventy-five percent of patients achieved long-term complete remission. I was determined to stay alive to receive CAR T therapy and in 2018, I was able to enroll in a phase 2 clinical trial of this therapy at UCLA. In just one month, it put me in a complete remission, something that none of my six previous therapies accomplished. On July 16, I will celebrate my seven-year CAR T birthday and thank my lucky stars for the NIH and the research funding that saved my life. And that little boy who was in kindergarten when I was diagnosed is now 25 years old. Laurie S. Adami, Los Angeles This story originally appeared in Los Angeles Times.
